Irish clinical research, pharmaceutical and biotechnology company Icon is forecasting earnings per-share between $1.40 and $1.52 for this year.
This compares with expected net income per diluted share of $1.27 to $1.29 for the year ended December 31st, 2008, the company said in a statement today.
The company also said net revenue was lower than expected during 2008 because of “currency factors”. Net sales will be between $930 million and $980 million this year.
